Literature DB >> 17570618

A descriptive epidemiology of substance use and substance use disorders in Nigeria during the early 21st century.

Oye Gureje1, Louisa Degenhardt, Benjamin Olley, Richard Uwakwe, Owoidoho Udofia, Abba Wakil, Olusola Adeyemi, Kipling M Bohnert, James C Anthony.   

Abstract

BACKGROUND: Several studies have examined the use of psychoactive substances among selected groups in Nigeria. Here, we extend the description to include the features of substance dependence.
METHOD: A stratified multi-stage random sampling of households was used to select respondents in 21 of Nigeria's 36 states (representing 57% of the national population). In-person interviews with 6752 adults were conducted using the World Health Organization Composite International Diagnostic Interview, Version 3. Lifetime history and recent (past year) use, as well as features of dependence on, alcohol, tobacco, cannabis, sedatives, stimulants, and other drugs were assessed.
RESULTS: Alcohol was the most commonly used substance, with 56% (95% confidence interval, CI=54, 58%) ever users and 14% (95% CI=13, 15%) recent (past year) users. Roughly 3% were recent smokers (3%, 95% CI=2.6, 4.2%). Next most common were sedatives, 4% (95% CI=2.3, 4.5%), and cannabis smokers, 0.4% (95% CI=0.1, 0.6%). Males were more likely than females to be users of every drug group investigated, with male preponderance being particularly marked for cannabis. Prevalence of both alcohol and tobacco use was highest among middle aged adults. Moslems were much less likely to use alcohol than persons of other faiths, but no such association was found for tobacco, non-prescription drug use, or illegal drug use. Features of abuse and dependence were more common at the population level for alcohol; but among users, these features were just as likely to be experienced by alcohol users as they were by other drug users.
CONCLUSION: Alcohol is the most commonly used psychoactive drug in Nigeria. Features associated with drug dependence and abuse are less prevalent but may require attention by public health authorities.

Entities:  

Mesh:

Year:  2007        PMID: 17570618     DOI: 10.1016/j.drugalcdep.2007.04.010

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  27 in total

1.  Epidemiology of psychoactive drug use amongst adolescents in metropolitan Lagos, Nigeria.

Authors:  Oluwole Famuyiwa; Olatunji F Aina; Olufunlayo M Bankole-Oki
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-06-29       Impact factor: 4.785

2.  Cross-national comparisons of sex differences in opportunities to use alcohol or drugs, and the transitions to use.

Authors:  J Elisabeth Wells; Josep Maria Haro; Eli Karam; Sing Lee; Jean-Pierre Lepine; Ma Elena Medina-Mora; Hideyuki Nakane; Jose Posada; James C Anthony; Hui Cheng; Louisa Degenhardt; Matthias Angermeyer; Ronny Bruffaerts; Giovanni de Girolamo; Ron de Graaf; Meyer Glantz; Oye Gureje
Journal:  Subst Use Misuse       Date:  2011-03-21       Impact factor: 2.164

3.  The epidemiological profile of alcohol and other drug use in metropolitan China.

Authors:  Hui Cheng; Sing Lee; Adley Tsang; Yueqin Huang; Zhaorui Liu; James C Anthony; Ronald C Kessler
Journal:  Int J Public Health       Date:  2010-02-16       Impact factor: 3.380

4.  Disability associated with mental disorders in metropolitan China: an application of the quantile regression approach.

Authors:  Hui Green Cheng; Yue-Qin Huang; Zhaorui Liu; Mingyuan Zhang; Sing Lee; Yucun Shen; Yanling He; James Christopher Anthony; Ronald C Kessler
Journal:  Psychiatry Res       Date:  2012-04-10       Impact factor: 3.222

5.  The epidemiology of drug use disorders cross-nationally: Findings from the WHO's World Mental Health Surveys.

Authors:  Louisa Degenhardt; Chrianna Bharat; Meyer D Glantz; Nancy A Sampson; Kate Scott; Carmen C W Lim; Sergio Aguilar-Gaxiola; Ali Al-Hamzawi; Jordi Alonso; Laura H Andrade; Evelyn J Bromet; Ronny Bruffaerts; Brendan Bunting; Giovanni de Girolamo; Oye Gureje; Josep Maria Haro; Meredith G Harris; Yanling He; Peter de Jonge; Elie G Karam; Georges E Karam; Andrzej Kiejna; Sing Lee; Jean-Pierre Lepine; Daphna Levinson; Victor Makanjuola; Maria Elena Medina-Mora; Zeina Mneimneh; Fernando Navarro-Mateu; José Posada-Villa; Dan J Stein; Hisateru Tachimori; Yolanda Torres; Zahari Zarkov; Somnath Chatterji; Ronald C Kessler
Journal:  Int J Drug Policy       Date:  2019-06-28

6.  Should Traffic Offenders Undergo Compulsory "Mental Test": A Study of Mental Health and Crash Involvement Among Commercial Motorcyclists in Ibadan, Nigeria?

Authors:  Olatunde O Ayinde; Olurotimi A Adejumo; O Olukolade; Victor O Lasebikan
Journal:  Community Ment Health J       Date:  2018-08-02

7.  Prevalence and correlates of illicit and non-medical use of psychotropic drugs in Japan: findings from the World Mental Health Japan Survey 2002-2004.

Authors:  Mayumi Tominaga; Norito Kawakami; Yutaka Ono; Yoshibumi Nakane; Yoshikazu Nakamura; Hisateru Tachimori; Noboru Iwata; Hidenori Uda; Hideyuki Nakane; Makoto Watanabe; Yoichi Naganuma; Toshiaki A Furukawa; Yukihiro Hata; Masayo Kobayashi; Yuko Miyake; Tadashi Takeshima; Takehiko Kikkawa
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-02-03       Impact factor: 4.328

8.  Prevalence of alcohol consumption and hazardous drinking, tobacco and drug use in urban Tanzania, and their associated risk factors.

Authors:  Joseph Mbatia; Rachel Jenkins; Nicola Singleton; Bethany White
Journal:  Int J Environ Res Public Health       Date:  2009-07-16       Impact factor: 3.390

9.  Alcohol use disorders in multidrug resistant tuberculosis (MDR-TB) patients and their non-tuberculosis family contacts in Nigeria.

Authors:  Victor Olufolahan Lasebikan; Olusoji Mayowa Ige
Journal:  Pan Afr Med J       Date:  2020-08-21

10.  Correlates of opium use: retrospective analysis of a survey of tribal communities in Arunachal Pradesh, India.

Authors:  Himanshu K Chaturvedi; Jagadish Mahanta; Ram C Bajpai; Arvind Pandey
Journal:  BMC Public Health       Date:  2013-04-10       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.